VivoSeq
Infectious Disease

HIV-1 Infection

129

Pipeline Programs↗

21

Active Trials↗

43

Companies Involved↗

HIV-1 infection is a highly competitive landscape with 129 programs across 43 companies. The most active players are BioNTech, Novo Nordisk, Essen Biotech. 35 therapies are approved with 21 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

36/100

Mech. Concentration

17/100

Completion Rate

82/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

BioNTech logo

BioNTech

2 programs

Phase 1Novo Nordisk logo

Novo Nordisk

1 program

Phase 1E

Essen Biotech

1 program

Phase 1Y

Y-mAbs Therapeutics

1 program

Phase 1A

Argos Therapeutics

1 program

Phase 1C

Chongqing Precision Biotech Co., Ltd

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical14

Nelfinavir Mesylate

Agouron Pharmaceuticals

Abacavir Sulfate

GSK

Disulfiram

Teva

Acetaminophen

Kenvue Brands

Nelfinavir

Agouron Pharmaceuticals

Phase 121

Estradiol

Novo Nordisk

Sargramostim

Sanofi

Thalidomide

Bristol-Myers Squibb

Raltegravir

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Maraviroc

GSK

Phase 238

Rifaximin

Salix

Zidovudine

Bp Consulting, Inc

Medroxyprogesterone Acetate

Eli Lilly

Peginterferon Alfa-2b

Merck & Co.

BCG Vaccine

Gynecologic Oncology Group

Phase 321

Saquinavir

Roche

Bictegravir

Gilead

Islatravir

Merck & Co.

Lenacapavir

Gilead

Ritonavir

AbbVie

Approved35

ATAZANAVIR

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Cannabidiol

Jazz Pharmaceuticals

DARUNAVIR

Wim Janssens

Isotretinoin

Conrado Roberto Hoffmann Filho

Niacin

AbbVie

Analysis

Modality Breakdown

87%

Small molecule

114 of 131 classified programs — the dominant modality here.

13%ALL OTHERSVaccine65%Monoclonal antibody43%Protein / enzyme43%Peptide22%Cell therapy1<1%

Small molecule leads; the ring shows all 131 classified programs, each share of the total. Modality classified for 88% of 166 pipeline programs.

Analysis

Trial Status

93

clinical trials

Completed47 · 51%
Unknown status13 · 14%
Terminated9 · 10%
Not yet recruiting9 · 10%
Recruiting7 · 8%
Active, not recruiting5 · 5%
Other3 · 3%

Clinical Trials

Trial Activity

93 trials

A Clinical Trial of STP0404 in Adults With HIV-1 Infection
Recruiting·SST Pharm Co., Ltd.·Phase 2·NCT05869643·36 enrolled
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection
Recruiting·AANRS, Emerging Infectious Diseases·Phase 3·NCT06203132·610 enrolled
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
Recruiting·AANRS, Emerging Infectious Diseases·Phase 2·NCT05300035·69 enrolled
A Multi-Center, Single-Arm, Open-Label, Prospective, Phase 4 Study to Investigate the Safety and Efficacy of Rapidly Restarting Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Viremic and Virologically-Suppressed Male and Female HIV-Positive Patients Aged ≥18 Years Who Are Treatment-Experienced and Returning to Care After Experiencing a Treatment Interruption of ≥12 Weeks
Recruiting·CCAN Community Health·Approved·NCT07476339·200 enrolled
A Phase 2 Randomized, Active-Controlled Study Evaluating the Safety and Efficacy of an Injectable Regimen of GS-3242 in Combination With Lenacapavir Versus Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide) in Virologically Suppressed People With HIV-1
Recruiting·Gilead logoGilead·Phase 2·NCT07645287·175 enrolled
IAP-086-1: A Phase 1 Single Ascending Dose First-Time in Human Study of the Safety, Tolerability and Pharmacokinetics of IAP086 in Persons With HIV-1 on Antiretroviral Therapy
Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 1·NCT07596888·30 enrolled
A Phase I First-in-human Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of the Broadly Neutralizing Antibody BNT351 in Adults Living Without and With HIV
Recruiting·BioNTech logoBioNTech·Phase 1·NCT07392372·67 enrolled
Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Active, not recruiting·Gilead logoGilead·Phase 2/3·NCT04150068·72 enrolled
Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
Active, not recruiting·Gilead logoGilead·Phase 3·NCT02842086·5,399 enrolled
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Active, not recruiting·Gilead logoGilead·Phase 2·NCT05729568·83 enrolled
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Active, not recruiting·—·Phase 2·NCT05527418·24 enrolled
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
Active, not recruiting·VVA Eastern Colorado Health Care System·Phase 1·NCT03729778·100 enrolled
Research on the Psychological Status of Patients With HIV-1 Infection
Not yet recruiting·SShanxi Bethune Hospital·N/A·NCT07080138·500 enrolled
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
Not yet recruiting·UUnited BioPharma·Phase 3·NCT04406727·50 enrolled
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Not yet recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06987318·40 enrolled
Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)